Recent News

• 04.25.2025 - Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
• 04.24.2025 - Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
• 04.17.2025 - Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
• 01.08.2025 - Addex to Present at the 2025 Swiss Equities Baader Conference
• 11.22.2024 - Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
• 11.11.2024 - Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
• 09.30.2024 - Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
• 09.19.2024 - Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
• 09.04.2024 - Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
• 08.27.2024 - Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Recent Filings

• 04.17.2025 - EX-99.1 EX-99.1
• 04.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.22.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.12.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.19.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.27.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2024 - SC 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.05.2024 - SC 13D/A General Statement of Acquisition of Beneficial Ownership